Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
31.50
+0.08 (0.25%)
At close: Jun 26, 2026, 4:00 PM EDT
31.39
-0.11 (-0.35%)
After-hours: Jun 26, 2026, 7:54 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Catalyst Pharmaceuticals stock have an average target of 32.4, with a low estimate of 31.5 and a high estimate of 35. The average target predicts an increase of 2.86% from the current stock price of 31.50.
Analyst Consensus: Hold
* Price targets were last updated on May 28, 2026.
Analyst Ratings
The average analyst rating for Catalyst Pharmaceuticals stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades $35 → $32 | Hold | Downgrades | $35 → $32 | n/a | May 28, 2026 |
| Citi | Citi | Hold Downgrades $35 → $32 | Hold | Downgrades | $35 → $32 | n/a | May 8, 2026 |
Unknown Analyst Robert W. Baird No rating | Robert W. Baird | Hold Downgrades $32 | Hold | Downgrades | $32 | +1.59% | May 7, 2026 |
| Oppenheimer | Oppenheimer | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 7, 2026 |
| Stephens | Stephens | Hold Downgrades $32 | Hold | Downgrades | $32 | +1.59% | May 7, 2026 |
Financial Forecast
Revenue This Year
636.20M
from 588.99M
Increased by 8.02%
Revenue Next Year
717.90M
from 636.20M
Increased by 12.84%
EPS This Year
3.17
from 2.72
Increased by 16.69%
EPS Next Year
3.18
from 3.17
Increased by 0.22%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 640.2M | 727.9M | |
| Avg | 636.2M | 717.9M | |
| Low | 632.2M | 702.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.7% | 14.4% | |
| Avg | 8.0% | 12.8% | |
| Low | 7.3% | 10.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.17 | 3.55 | |
| Avg | 3.17 | 3.18 | |
| Low | 3.17 | 2.58 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 16.7% | 11.8% | |
| Avg | 16.7% | 0.2% | |
| Low | 16.7% | -18.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.